Table 1 Summary and characteristics of patients (patients, N = 35)
Characteristic | Â |
|---|---|
Age (years, median) (range) | 58 (34–80) |
Gender | |
 Male | 16 (45.7%) |
 Female | 19 (54.3%) |
BMI kg/m2 (mean) (range)b | 23.7 (17.0–33.7) |
Cancer type | |
 Adenocarcinoma | 34 (97.1%) |
 Neuroendocrine carcinoma | 1 (2.9%) |
Initial systemic chemotherapy | |
 FOLFIRI | 33 (94.2%) |
 FOLFOXIRI | 1 (2.9%) |
 Cisplatin + Etoposide | 1 (2.9%) |
1st line combined target therapy | |
 Bevacizumab | 27 (77.1%) |
 Cetuximab | 6 (16.1%) |
 Panitumumab | 1 (2.9%) |
 None | 1 (2.9%) |
Colectomy | |
 Yes | 20 (57.1%) |
 No | 15 (42.9%) |
Primary tumor location | |
 Right colon | 7 (20.0%) |
 Left colon | 28 (80.0%) |
Metastasis condition | |
 Synchronous metastasis | 30 (85.7%) |
 Metachronous metastasis | 5 (14.3%) |
Extrahepatic metastasisa | |
 Yes (%) | 13 (37.1%) |
 Lung (% of total metastasis) | 5 (14.3%) |
 Para-aortic lymph node (% of total metastasis) | 6 (17.1%) |
 Peritoneum (% of total metastasis) | 3 (8.6%) |